USE OF BRADYCARDIAC SUBSTANCES IN THE TREATMENT OF MYOCARDIAL DISEASES ASSOCIATED WITH HYPERTROPHY AND NOVEL MEDICAMENT COMBINATIONS

Primena zatebradina, cilobradina ili alinidina, i opciono kardioaktivnog jedinjenja, za dobijanje leka za lečenje miokardnih oboljenja povezanih sa hipertrofijom.Prijava sadrži još 4 patentna zahteva. A medicament (A) for treating myocardial diseases associated with hypertrophy contains a bradycardi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	GUTH, BRIAN DR, SEIDLER, RANDOLPH DR, DAEMMGEN, JUERGEN DR
Format:	Patent
Sprache:	eng ; srp
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Primena zatebradina, cilobradina ili alinidina, i opciono kardioaktivnog jedinjenja, za dobijanje leka za lečenje miokardnih oboljenja povezanih sa hipertrofijom.Prijava sadrži još 4 patentna zahteva. A medicament (A) for treating myocardial diseases associated with hypertrophy contains a bradycardic agent (I) and optionally another cardiac drug (II). ACTIVITY : Cardiant. In tests in a cat having severe hypertrophic cardiomyopathy, oral administration of cilobradine (Ia) twice daily at 0.3 mg/kg marked reduced the clinical symptoms (e.g. by reducing pain and normalizing the ECG) and also caused regression of the myocardial hypertrophy after 1 and 2 years. MECHANISM OF ACTION : Calcium ion channel blocker; beta -receptor blocker; i f channel blocker.